Silo Pharma (NASDAQ: SILO) announced encouraging early results from its ongoing study evaluating the pharmacokinetics, safety and tolerability of it ...

It’s a significant finding because, to date, most studies of ketamine in depression have relied on either intravenous or intranasal administration, the latter resulting in the approval of J&J ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato ... The drug is the first ketamine-based medicine approved to treat depression. Ketamine has long been seen as a potential ...

Objective: Prior research has shown that ketamine has anti-suicide effects. Additional evidence also suggests that ketamine may offer pro-cognitive effects. Herein, we propose that the anti-suicide ...